Avvio Medical shares groundbreaking trial results at AUA 2025
- Results from the AEROLITH randomized clinical trial will be presented at the 2025 AUA Annual Meeting in Las Vegas, Nevada.
- The study evaluates the safety and effectiveness of Acoustic Enhancer Microbubble Cavitation with ureteroscopic laser lithotripsy for treating kidney and ureteral stones.
- This presentation adds to the growing evidence supporting the technology developed by Avvio Medical and addresses the need for improved strategies in stone management.
In a significant development for the medical community, Avvio Medical Inc., previously known as Applaud Medical, announced on April 25, 2025, that it would present results from its AEROLITH randomized clinical trial at the upcoming American Urological Association (AUA) Annual Meeting in Las Vegas, Nevada. The event is scheduled to take place from April 26 to 29, 2025, attracting professionals from the urological field to discuss innovations and advancements in treatment strategies. The AEROLITH study focused on evaluating the safety and effectiveness of the company's Acoustic Enhancer Microbubble Cavitation (AEMC) technology when used in conjunction with ureteroscopic laser lithotripsy (URS-LL) for addressing kidney and ureteral stones. With the increasing prevalence of such conditions and the demand for improved treatment options, the study aimed to provide compelling evidence for the practical applications of this innovative approach. Paul Molloy, the President and Chief Executive Officer of Avvio Medical, emphasized the urgent need for enhanced methods in stone management, reflecting the challenges faced by both patients and healthcare providers. The findings from the AEROLITH trial are expected to contribute to the growing support for Avvio's proprietary technology, which aims to streamline the treatment process while offering potential clinical and economic advantages without relying on general anesthesia or X-ray imaging. During the conference, Dr. Wesley Mayer will lead a moderated interactive poster presentation titled IP08-22 on April 26th between 3:30 and 5:30 PM in Room Marco Polo 701. This presentation will provide insights into the study's results and their implications for the future of urologic treatment. As health professionals gather to learn about advancements such as the Enhanced Lithotripsy System (ELS), the information presented may significantly influence the standard care practices regarding stone management and patient experience in urologic procedures.